Nucleic Acid-Based Drugs as Antiviral Agents

PDF

Authors
  1. Saravolac, E.G.
  2. Sun, L-Q.
  3. Cairns, M.J.
  4. Wong, J.P.
Corporate Authors
Defence R&D Canada - Toronto, Toronto ONT (CAN)
Abstract
Nucleic acid-based drugs are promising classes of therapeutic agents that have important clinical applications for the prevention and treatment of viral diseases. This review highlights the applications of three main classes of oligonucleotides that are designed to suppress, inhibit and /or knock out virus gene expression. Antisense oligonucleotides have a high level of specificity and affinity for target genes and have been shown to be efficacious in the treatment of various virus infections, including HIV, hepatitis, and human papilloma viruses. Catalytic DNAzymes are DNA-based enzymes with considerable potential as they have the ability to cleave RNA transcripts at purine-pyrimidine junctions, and they do so with high level of target site flexibility. Similarly, ribozymes are catalytic RNA enzymes engineered to cleave target RNA in a sequence-specific manner. Among these are the hammerhead and hairpin ribozymes that are particularly useful for gene therapy of clinically relevant virus diseases. This review will focus on the design, mode of action, efficacy of these groups of oligonucleotides, and the evaluation of these agents from in vitro activity to efficacy in animal protection studies, through to safety in clinical trials.
Keywords
Oligonucleotide analysis;Human immunodeficiency virus (HIV)
Report Number
DRDC-TORONTO-SL-2002-122 — Reprint
Date of publication
22 Apr 2003
Number of Pages
26
Reprinted from
Recent, Devel, Antiviral Res., Vol 1,2001, p 117-141
DSTKIM No
CA022242
CANDIS No
519115
Format(s):
Hardcopy

Permanent link

Document 1 of 1

Date modified: